BiotechTube
Home/Spexis/Jeffrey D. Wager, M.D.
JD

Jeffrey D. Wager, M.D.

Chief Executive Officer

Spexis

Therapeutic Areas

Rare DiseasesOncologyInfectious Diseases

Spexis Pipeline

DrugIndicationPhase
ColiFin®Cystic FibrosisMarketed (EU)
Inhaled MurepavadinCystic Fibrosis (Pseudomonas aeruginosa infection)Phase 1
OMPTA LPS & BamA ProgramMultidrug-Resistant Gram-negative InfectionsPre-clinical
OMPTA LptA Thanatin ProgramMultidrug-Resistant Gram-negative InfectionsPre-clinical

Leadership Team at Spexis

JF
Juergen Froehlich, M.D.
Chief Medical Officer
View full Spexis profile